Table 1

Patient demographics and clinical characteristics.

Patient number

Sex

Diagnosis

Site involvement

Reason for inclusión

ANA/dsDNAα antibodies

Anti-Ro/SSA/La/SSB antibodies

CLASI A/D

Previous received treatment


1

F

DLE (L)

V-neck, arm

T lack of efficacy, PN

1/640 (123)

+/-

6/2

TCS, OCS, HCQ, T

2

F

Lupus Profundus

Arm, back

T lack of efficacy

1/160 (-)

-/-

7/1

TCS, OCS, HCQ, T

3

F

DLE (L)

Arm

T lack of efficacy

1/640 (-)

-/-

3/1

TCS, OCS, HCQ, T

4

F

ACLE

Face, v-neck

T side effects

1/640 (54)

-/-

6/0

TCS, OCS, HCQ, T, AZA,

5

F

Lupus Profundus

Scalp, face, arms

T side effects

1/640 (144)

-/-

19/6

TCS, OCS, HCQ, MMF, T

6

F

SCLE

Face, v-neck, back

> 18% body surface

1/640 (-)

+/-

19/0

TCS, OCS, MMF

7

F

SCLE

Face, v-neck, hands, arms

T side effects, PN, > 18% body surface

1/640 (83)

-/-

20/1

TCS, OCS, HCQ, AZA, T

8

F

DLE (L)

Face, scalp, ear lobe

T side effects

1/40 (-)

-/-

9/0

TCS, OCS, HCQ, T

9

F

DLE (G)

Face, ear lobe, arms, neck

> 18% body surface, T side effects

1/320 (37)

-/-

13/2

TCS, OCS, HCQ, MMF, T

10

F

LET

Face

T side effects, PN

1/640 (-)

-/-

6/0

TCS, HCQ, T

11

F

DLE (G)

Face, scalp, back

T side effects, > 18% body surface

1/40 (-)

+/-

15/9

TCS, OCS, HCQ, T

12

F

DLE (G)

Face, v-neck, back, scalp

T side effects, PN

1/40 (-)

+/-

17/8

TCS, OCS, HCQ, T

13

F

DLE (L)

Face

T lack of efficacy

1/160 (-)

-/-

3/0

TCS, HCQ, T

14

F

DLE (G)

Face, v-neck

T side effects

1/640 (-)

-/-

11/2

TCS, OCS, HCQ, MMF, T

15

F

DLE (L)

Face, scalp

T side effects

1/40 (-)

-/-

10/3

TCS, OCS, HCQ, T


αNormal value of anti-dsDNA antibodies is < 15 IU/ml. A, activity; ACLE, acute cutaneous lupus erythematosus; ANA, antinuclear antibodies; AZA, azathioprine; CLASI, Cutaneous Lupus Erythematosus Disease Area and Severity Index; D, damage; DLE, discoid lupus erythematosus; G, generalized; HCQ, hydroxychloroquine; L, localized; LET, lupus erythematosus tumidus; MMF, mycophenolate mofetil; OCS, oral corticosteroids; PN, polyneuropathy; SCLE, subacute cutaneous lupus erythematosus; T, thalidomide; TCS, topical steroids.

Cortés-Hernández et al. Arthritis Research & Therapy 2012 14:R265   doi:10.1186/ar4111

Open Data